Neurotransmitter Markers of Depression

References

• Hollister L. E. Treatment of depression. Ann Int Med 1978; 89: 78–84
   PubMed Web of Science ®Google Scholar
• Goldberg D., Huxley P. Mental illness in the community. Tavistock, London 1980
   Google Scholar
• Watts C. A. H. Depressive disorders in the community. John Wright, Bristol 1965
   Google Scholar
• Carr A. C., Ancill R. J., Ghosh A., Margo A. A Direct assessment of depression by micro computer. Acta Psychiat Scand 1981; 64: 415–422
   PubMedGoogle Scholar
• Schildkraut J. J., Orsulak P. J., Schatzberg A. F., et al. Towards a biochemical classification of depressive disorders 1. Differences in urinary excretion of MHPG and other catecholamine metabolites in clinically defined subtypes of depression. Arch Gen Psychiat 1978; 35: 1427–1433
   PubMedGoogle Scholar
• Van Praag H., De Hahn S. Central serotonin metabolism and frequency of depression. Psychiat Res 1979; 1: 219–224
   PubMed Web of Science ®Google Scholar
• Leonard B. E. Current status of the biogenic amine theory of depression. Neurochem Int 1982; 4: 339–350
   PubMedGoogle Scholar
• Montgomery S. A. The non-selective effect of selective antidepressants. Adv Biochem Psychopharmac 1982; 31: 49–56
   Google Scholar
• Veith R. C., Bielski R. J., Bloom V., et al. Urinary MHPG excretion and treatment with desipramine or amitripthline: prediction of response, effect of treatment and methodological hazards. J Clin Psychopharmac 1983; 3: 18–27
   PubMedGoogle Scholar
• Wyatt R. J., Portnoy B., Kupfer D. J., et al. Resting plasma catecholamine concentrations in patients with depression and anxiety. Arch Gen Psechiat 1971; 24: 65–70
   PubMed Web of Science ®Google Scholar
• Shimizu T., Fujita M. Effects of β-adrenergic receptor blocking agents in depression as measured by plasma noradrenaline concentration and blood pressure. New vistas in depression, S. Z. Langer. Pergamon Press, New York 1981
   Google Scholar
• Mikhailidis D., Luck D. P., Dashwood M. R., et al. Platelet hyper-aggregability and increased α-adrenoceptor density in anorexia nervosa. Clin Endocrinol Metab 1983; 57: 911–914
   Google Scholar
• Raisman R., Driley M. S., Langer S. Z. Specific tricyclic antidepressant binding sites in rat brain. Nature 1979; 281: 148–149
   PubMed Web of Science ®Google Scholar
• Langer Zarifian S.Z., Brileysm E., et al. High-affinity binding of 3H-impipramine in brain and platelets and its relevance to the biochemistry of affective disorders. Life Sci 1981; 29: 211–218
   PubMed Web of Science ®Google Scholar
• Vetulani J., Stawarz R. J., Dingell J. V., et al. A possible common mechanism of action of antidepressant treatments. NS Arch Pharmac 1976; 293: 109–114
   PubMed Web of Science ®Google Scholar
• Kant G. J., Bates V. E., Lenox R. A., et al. Effects of acute and chronic descimethylimipramine on levels of cyclic AMP in vivo. Biochem Pharmac 1983; 32: 732–735
   Google Scholar
• Sulser F., Janowsky A. J., Okada F., et al. Regulation of recognition and action function of the norepinephrine receptor-coupled adenylate cyclase system in brain: implications for the therapy of depression. Neuropharmac 1983; 22: 425–431
   PubMed Web of Science ®Google Scholar
• Starke K. Regulation of noradrenaline release by pre-synaptic receptor systems. Rev Physiol Biochem Pharmac 1977; 77: 1–24
   PubMed Web of Science ®Google Scholar
• Pletscher A. Platelets as models for monoaminergic neurons. Essays in neurochemistry and neuropharmacology. Karger, Basel 1975; Vol. 4: 328–342
   Google Scholar
• Davies I. B., Mathias C. J., Sudera D., et al. Agonist regulation of α-adrenergic receptors in man. J Cardiovasc Pharmac 1982; 4: SI38–SI40
   Google Scholar
• Jung R. T., Shetty P. S., Barrand M., et al. Role of catecholamines in hypotensive response to dieting. Br Med J 1979; 1: 12–24
   PubMed Web of Science ®Google Scholar
• Lampugnani M. G., De Gaetano G. Comparative effects of ketanserin, a novel serotonergic receptor antagonist, on 5-HT induced shape change and 5-HT uptake in rat and human platelets. Biochem Pharmac 1982; 31: 3000–3002
   PubMedGoogle Scholar
• Healy D., Carney P. A., Leonard B. E. Monoamine-related markers of depression: changes following treatment. J Psychiat Res 1983; 17: 251–260
   Web of Science ®Google Scholar
• Wirz-Justice A., Campbell I. C. Antidepressant drugs can slow or dissociate circadian rhythms. Experientia 1982; 38: 1301–1309
   PubMedGoogle Scholar
• Kafka M. S., Wirz-Justice A., Naber D., et al. Effect of lithium on circadian neurotransmitter receptor rhythms. Neuropsychobiol 1982; 8: 41–50
   PubMed Web of Science ®Google Scholar
• Goodwin F. K., Wirz-Justice A., Wehr T. A. Evidence that the pathophysiology of depression and the mechanism of action of antidepressant drugs both involve alterations in circadian rhythms. Adv Biochem Psychopharmac 1982; 31: 1–11
   Google Scholar
• Mendlewicz J., Van Praag H. M. Biological rhythms and behaviour. Adv Biol Psychiat 1983; 11
   Google Scholar
• Olpe H. R. Molecular view of the treatment of depression. Depression: molecular and psychologically based therapies, J. Korf, L. Pepplinkhuizen. TGO Drachtcn, Holland, TGO Foundation 1983; 21–45
   Google Scholar
• Garrer D. L., Pandey S. N., Dekirmenjian H., et al. Growth hormones and catecholamines in affective disease. Am J Psychiat 1975; 132: 1149–1154
   Google Scholar
• Carroll B. J., Mendels J. Neuroendocrine regulation in affective disorders. Hormones, behaviour and psychopathology, D. De Wied. Raven Press, New York 1976; 193–224
   Google Scholar
• Meltzer H. Y., Fang V. S. Central determination and the dexamethasone suppression test. Arch Gen Psychiat 1983; 40: 501–505
   PubMedGoogle Scholar
• Asnis G. M., Sachar E. J., Halbreich U. Cortisol secretion and dexamethasone response in depression. Am J Psychiat 1981; 138: 1218–1221
   PubMed Web of Science ®Google Scholar
• Carroll B. J., Feinberg M., Greden J. F., et al. A specific laboratory test for the diagnosis of melancholia. Standardisation, validation and clinical utility. Arch Gen Psychiat 1981; 38: 15–22
   PubMed Web of Science ®Google Scholar
• Ballin J., Gottfries C.-G, Karlsson I., et al. Dexamethasone suppression test and serum prolactin in dementia disorders. Br J Psychiat 1983; 143: 277–281
   Google Scholar
• Brambilla F., Smeraldi E., Sacchetti E., et al. Deranged anterior pituitary responsiveness to hypothalamic hormones in depressed patients. Arch Gen Psychiat 1978; 35: 1231–1238
   PubMed Web of Science ®Google Scholar
• Matussek N., Romisch P., Mhpg Ackenheil M. excretion during sleep deprivation in endogenous depression. Neuropsychobiol 1977; 3: 23–29
   Google Scholar
• Langer G., Heinze G., Reim B., et al. Growth hormone response to d-amphetamine in normal controls and in depressed patients. Neurosci Leu 1975; 1: 185–189
   Google Scholar
• Tuomisto J., Rukiainen E., Ahlfors U. G. Decreased uptake of 5-hydroxytryptamine in blood platelets from patients with endogenous depression. Psychopharmac 1979; 65: 141–147
   Google Scholar
• Boullin D. J., Glenton P. A. M. Characterisation of receptors mediating 5-HT and catecholamine induced platelet aggregation assessed by the actions of α and β-blockers, butyrophenones. 5-HT antagonists and chlorpromazine. Br J Pharmac 1978; 62: 537–542
   PubMedGoogle Scholar
• Kafka M. S., Smith C. C. Alpha-adrenergic receptors on human platelets. Life Sci 1977; 21: 1429–1438
   PubMed Web of Science ®Google Scholar
• Williams L. T., Lefkowitz R. J. Identification of β-adrenergic receptors in human lymphocytes by H-alprenolol binding. J Lab Clin Med 1976; 57: 149–155
   Google Scholar
• Wagner H. R., Crutcher K. A., Davis J. N. Chronic estrogen treatment decreases β-adrenergic responses in rat cerebral cortex. Brain Res 1979; 171: 147–151
   Google Scholar